Centessa Pharmaceuticals plc (CNTA)
- Previous Close
8.93 - Open
8.90 - Bid 8.86 x 100
- Ask 8.96 x 400
- Day's Range
8.70 - 9.11 - 52 Week Range
3.96 - 12.45 - Volume
254,924 - Avg. Volume
410,022 - Market Cap (intraday)
894.73M - Beta (5Y Monthly) 1.38
- PE Ratio (TTM)
-- - EPS (TTM)
-1.57 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
13.60
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
www.centessa.comRecent News: CNTA
Performance Overview: CNTA
Trailing total returns as of 4/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CNTA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CNTA
Valuation Measures
Market Cap
895.73M
Enterprise Value
723.77M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
125.33
Price/Book (mrq)
3.79
Enterprise Value/Revenue
105.61
Enterprise Value/EBITDA
-4.38
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.61%
Return on Equity (ttm)
-52.79%
Revenue (ttm)
6.85M
Net Income Avi to Common (ttm)
-151.08M
Diluted EPS (ttm)
-1.57
Balance Sheet and Cash Flow
Total Cash (mrq)
256.55M
Total Debt/Equity (mrq)
36.02%
Levered Free Cash Flow (ttm)
-97.11M